<DOC>
	<DOC>NCT00157300</DOC>
	<brief_summary>Randomized, double blind, placebo controlled, prospective trial investigating the effect of erythropoietin in renal transplantation. The investigators postulate that erythropoietin reduces the risk of delayed graft function.</brief_summary>
	<brief_title>PROTECT: Prospective Trial on Erythropoietin in Clinical Transplantation</brief_title>
	<detailed_description>Randomized, double blind, placebo controlled, prospective trial in patients, receiving a kidney transplantation. Patients will be randomized to receive either Epoetin Beta (Neorecormon; Roche) or placebo. The primary endpoint will be delayed graft function. The anticipated duration of this trial is 2 year and the target sample size is 60 patients per arm.</detailed_description>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Adult patients Receiving a kidney from a nonheartbeating donor category 3 Donor related factors: a prolonged warm ischaemic time (&gt; 45 min); a cold ischaemic time of &gt; 24 hours; serum creatinin of &gt; 150 umol/l</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>erythropoietin</keyword>
	<keyword>kidney transplantation</keyword>
	<keyword>delayed graft function</keyword>
</DOC>